Three-year survival hits 83% as Johnson & Johnson expands TECVAYLI into second-line myeloma

Johnson & Johnson has secured a major expansion for its multiple myeloma franchise after the European Commission approved TECVAYLI, or teclistamab, with daratumumab for adults with relapsed or refractory multiple myeloma after at least one prior therapy. The decision moves the BCMA-directed bispecific antibody much earlier in treatment and is supported by Phase 3 MajesTEC-3 data showing an 83.4% reduction in the risk of progression or death compared with established daratumumab-based regimens. Three-year overall survival reached 83.3% with TECVAYLI plus daratumumab versus 65.0% with standard treatment, while complete responses or better were achieved by more than four-fifths of patients receiving the combination. For Johnson & Johnson, the approval broadens the commercial opportunity for an oncology franchise already helping drive growth across its $16.4 billion quarterly Innovative Medicine business.

The strategic significance comes from treatment timing. TECVAYLI originally entered Europe for heavily pretreated patients who had already received at least three prior therapies, but the new indication allows the combination after only one previous line. That places an off-the-shelf bispecific regimen into a substantially larger and clinically healthier population, where longer treatment duration and deeper responses could translate into a more valuable commercial opportunity if physicians adopt the combination broadly. Johnson & Johnson is effectively moving TECVAYLI upstream from a rescue therapy toward a potential cornerstone of relapsed multiple myeloma treatment.

MajesTEC-3 gives Johnson & Johnson unusually strong evidence for moving TECVAYLI earlier in myeloma care

The randomized Phase 3 MajesTEC-3 trial enrolled 587 patients who had received between one and three previous lines of treatment. Patients received either TECVAYLI plus subcutaneous daratumumab or investigator-selected standard therapy consisting of daratumumab and dexamethasone combined with pomalidomide or bortezomib. Progression-free survival served as the primary endpoint, with overall survival, response depth, minimal residual disease negativity, safety and patient-reported outcomes providing additional measures of clinical benefit.

After nearly three years of follow-up, the hazard ratio for progression or death was approximately 0.17, corresponding to the 83.4% risk reduction that underpins the European approval. More than 90% of patients who remained progression free after six months were still progression free at three years, indicating unusually durable disease control among early responders. Overall survival also favored the combination, with a roughly 54% reduction in the risk of death and an 18.3 percentage-point advantage in three-year survival.

The depth of response provides another reason the results could alter treatment sequencing. Overall response reached 89% with TECVAYLI plus daratumumab compared with 75.3% in the control group, while complete response or better reached 81.8% versus 32.1%. Minimal residual disease negativity was reported in 58.4% of patients receiving the bispecific combination compared with only 17.1% on standard regimens. These results suggest the regimen is not merely delaying progression but driving substantially deeper suppression of malignant plasma cells.

That distinction matters in a disease where virtually all patients ultimately face relapse. Multiple myeloma treatment has increasingly focused on driving the deepest possible remission earlier because each subsequent relapse can become more difficult to control. Moving TECVAYLI into second-line treatment therefore gives Johnson & Johnson access to patients before extensive prior therapy compromises immune function or limits future therapeutic options.

Earlier-line TECVAYLI could strengthen an oncology franchise already driving Innovative Medicine growth

The commercial backdrop is favorable. Johnson & Johnson generated $25.31 billion of worldwide second-quarter 2026 sales, up 6.6% year over year, while Innovative Medicine revenue increased 7.8% to $16.38 billion. Management specifically identified DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT with LAZCLUZE as major drivers of oncology growth during the quarter.

That performance is particularly important because Johnson & Johnson is navigating declining sales from older products such as STELARA, IMBRUVICA and ZYTIGA. Expanding newer oncology medicines into earlier treatment lines helps replace revenue exposed to biosimilar competition and product maturity while extending the lifecycle of internally developed franchises. The company raised its full-year 2026 reported sales outlook in July to between $100.8 billion and $101.4 billion, with the midpoint implying approximately 7.3% growth.

TECVAYLI now fits directly into that replacement strategy. A medicine used only after three or four previous treatments addresses a relatively small population with limited treatment duration, while second-line eligibility expands both the number of potential patients and the period during which therapy can contribute revenue. The economic opportunity becomes larger again if future studies support additional combinations or even earlier treatment.

Johnson & Johnson is also building several complementary multiple myeloma assets rather than relying exclusively on TECVAYLI. DARZALEX is already one of the dominant antibody therapies in the disease, CARVYKTI offers BCMA-directed CAR T-cell therapy, and TALVEY provides a bispecific antibody aimed at GPRC5D. This creates the possibility of treatment sequencing across several proprietary mechanisms as patients progress through the disease, potentially allowing Johnson & Johnson to retain patients within its oncology portfolio across multiple lines of therapy.

The TECVAYLI and daratumumab pairing is strategically powerful because both medicines belong to that same broader franchise. Rather than combining TECVAYLI with a competitor’s backbone, Johnson & Johnson can generate value from two established products while using daratumumab’s CD38 targeting and immunomodulatory effects to complement TECVAYLI’s BCMA-directed T-cell engagement.

Infection risk remains the biggest counterweight to the combination’s striking survival advantage

The efficacy numbers are difficult to ignore, but the safety profile means the combination is not a low-intensity alternative to conventional therapy. Grade 3 or Grade 4 treatment-emergent adverse events occurred in more than 95% of patients in both study groups, reflecting the advanced disease and treatment intensity involved in relapsed multiple myeloma. Severe cytopenias and infections accounted for many of those events.

Infections were particularly notable with TECVAYLI plus daratumumab. Any-grade infections occurred in 96.5% of patients receiving the combination compared with 84.1% in the control group, while Grade 3 or Grade 4 infections occurred in 54.1% versus 43.4%. Johnson & Johnson reported that severe infection rates declined after the first six months as patients received preventive measures, immunoglobulin supplementation and transitioned toward less frequent TECVAYLI dosing.

Cytokine release syndrome occurred in approximately 60% of patients receiving the bispecific regimen, although events were limited to Grade 1 or Grade 2 and did not lead to treatment discontinuation. Immune effector cell-associated neurotoxicity syndrome was comparatively uncommon. These findings suggest the regimen can be managed successfully in experienced centers, but they also create additional monitoring and supportive-care requirements that could affect how quickly community oncology practices adopt earlier-line bispecific treatment.

That implementation challenge could become increasingly important as Johnson & Johnson attempts to move TECVAYLI beyond specialist centers. The product has the logistical advantage of being manufactured in advance rather than individually produced for each patient like CAR T-cell therapy, but off-the-shelf availability does not eliminate the need for careful management of immune complications and infection risk.

European approval reinforces the shift of bispecific antibodies from salvage therapy into mainstream relapse treatment

The European Commission decision follows United States approval of TECVAYLI plus DARZALEX FASPRO earlier in 2026 for certain adults with relapsed or refractory multiple myeloma after at least one prior treatment. With both major markets now supporting earlier use, the commercial debate increasingly shifts from whether bispecific antibodies can work in advanced disease to how quickly they can challenge established second-line combinations.

Johnson & Johnson has additional evidence supporting that transition. The MajesTEC-9 study has also produced positive Phase 3 results for TECVAYLI monotherapy as early as first relapse in patients predominantly refractory to anti-CD38 treatment and lenalidomide. That creates several possible routes for TECVAYLI across the relapsed population depending on previous treatment exposure and patient characteristics.

Competition remains intense because multiple myeloma has become one of oncology’s fastest-moving treatment markets, with CAR T-cell therapies, antibody-drug combinations and bispecific antibodies all moving toward earlier disease. Johnson & Johnson’s advantage is the breadth of its portfolio and the ability to combine proprietary medicines rather than competing with a single asset.

The European decision therefore has implications beyond incremental TECVAYLI sales. It strengthens Johnson & Johnson’s ability to build treatment pathways around DARZALEX, TECVAYLI, CARVYKTI and TALVEY and potentially capture value across multiple successive stages of myeloma care.

Johnson & Johnson stock sentiment remains strong after a 30% rally despite near-term volatility

Johnson & Johnson shares entered August 21 after closing the previous session around $267.37 following a roughly 2.2% daily decline. Despite that pullback, the stock remained approximately 30.5% higher for 2026, reflecting broadly positive sentiment toward the company’s earnings growth, improving pipeline and expanding portfolio rather than the TECVAYLI program alone. A morning market snapshot on August 21 showed shares around $267.74 before regular trading began.

The stock’s strong year-to-date performance means new drug approvals are being evaluated against already elevated expectations. Johnson & Johnson has raised its 2026 sales and adjusted earnings guidance, quarterly revenue has moved above $25 billion and Innovative Medicine continues to grow despite substantial pressure from STELARA erosion.

The TECVAYLI expansion therefore reinforces rather than transforms the existing investment thesis. One European label change is unlikely to materially alter a company with more than $100 billion of expected annual revenue, but the approval supports the more important long-term argument that newer oncology products can replace mature franchises and continue driving above-market growth.

For Johnson & Johnson, the real value of MajesTEC-3 may emerge over several years as bispecific antibodies move deeper into routine multiple myeloma care. An 83.4% reduction in progression or death, an 83.3% three-year survival rate and complete responses in more than 80% of treated patients give TECVAYLI unusually strong evidence for that transition. The commercial question is now whether physicians can reproduce those benefits broadly while managing infection risk sufficiently well to turn earlier-line approval into durable market share.

Key takeaways on what TECVAYLI’s European approval means for Johnson & Johnson

• The European Commission approved TECVAYLI plus daratumumab for relapsed or refractory multiple myeloma after at least one prior therapy, substantially broadening earlier-line use.
• MajesTEC-3 showed an 83.4% reduction in the risk of disease progression or death compared with established daratumumab-based regimens.
• Three-year overall survival reached 83.3% with TECVAYLI plus daratumumab compared with 65.0% in the control group.
• Complete response or better reached 81.8%, while minimal residual disease negativity reached 58.4%, indicating unusually deep disease control.
• Moving TECVAYLI from heavily pretreated disease into second-line therapy materially expands its addressable commercial population.
• Johnson & Johnson’s Innovative Medicine division generated $16.38 billion in second-quarter sales, with TECVAYLI and DARZALEX among the products driving oncology growth.
• Johnson & Johnson raised its 2026 reported sales outlook to $100.8 billion to $101.4 billion as newer medicines offset pressure from mature products.
• Infection remains the most important safety consideration, with Grade 3 or Grade 4 infections occurring more frequently with TECVAYLI plus daratumumab than control therapy.
• Johnson & Johnson is building a broad multiple myeloma portfolio around TECVAYLI, DARZALEX, CARVYKTI and TALVEY, potentially supporting treatment across several lines of disease.
• JNJ shares remained roughly 30.5% higher for 2026 despite recent volatility, indicating broadly positive investor sentiment toward the company’s growth and pipeline execution.